Treatment of type 2 diabetes: A structured management plan

Advances in Therapy

Volumn 25, Issue 2, 2008, Pages 106-114

  Baxter, Mike ^a  

^a ASHFORD AND ST PETER'S HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Algorithm; Glycosylated haemoglobin; Management; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ALGORITHM; ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; PRACTICE GUIDELINE; RISK REDUCTION; WEIGHT REDUCTION; REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 58749109171     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0017-y     Document Type: Article

References (24)

1. British Heart Foundation web site. Available at: www.heartstats.org. Accessed January 2007. January 2007.
2. World Health Organization web site. Available at: www.who.int. Accessed January 2007.
3. Smith NL, Barzilay JI, Kronmal R, Lumley T, Enquobahrie D, Psaty BM. New onset diabetes and risk of all-cause and cardiovascular mortality: The cardiovascular health study. Diabetes Care. 2006;29:2012-2017.
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
5. The DCCT Research Group. The relationship of glycaemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968-983.
6. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
7. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111.
8. Barnett AH. Treating to goal: Challenges of current management. Eur J Endocrinol. 2004;151:T3-T7.
9. Diabetes UK. Diabetes: State of the Nations 2006. Progress Made in Delivering the National Diabetes Frameworks. London: Diabetes UK; 2006.
10. Simmons D. Personal barriers to diabetes care: Is it me, them or us? Diabetes Spectrum. 2001;14:10-12.
11. Lawton J, Ahmad N, Hallowell N, et al. Perceptions and experiences of taking oral hypoglycaemic agents among people of Pakistani and Indian origin: Qualitative study. BMJ. 2005;330:1247.
12. Davies M, Storms F, Shutler S, et al. Improvement in glycaemic control in subjects with poorly controlled type 2 diabetes. Comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282-1288.
13. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: New pharmacologic approaches to improve glycaemic control. Curr Med Res Opin. 2007;23:905-917.
14. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963-1972. Erratum in: Diabetes Care. 2006;49:2816-2818.
15. Turner R, Cull C, Frighi V, Holmann R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) group. JAMA. 1999;281:2005-2012.
16. Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2002;25:1737-1743.
17. The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Lancet. 2006;368:1096-1105.
18. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROoactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitzone Clinical Trial in Macrovascular Events): A randomised controlled trial. Lancet. 2005;8:366:1279-1289.
19. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
20. Bolli GB. The pharmacokinetic basis of insulin therapy in diabetes mellitus. Diabetes Res Clin Pract. 1989;6:S3-S16.
21. Binder C, Lauritzen T, Faber O, Praming S. Insulin pharmacokinetics. Diabetes Care. 1984;7:188-199.
22. Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26:S18-S24.
23. Campbell RK, White JR Jr. Insulin therapy in type 2 diabetes. J Am Pharm Assoc (Wash). 2002;42:602-611.
24. Danne T, Lupke K, Walte K, et al. Insulin determir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents and adults with type 1 diabetes. Diabetes Care. 2003;26:3087-3092.